Al Ameri Mubarak Nasser, Nayuni Nanda, Anil Kumar K G, Perrett David, Tucker Arthur, Johnston Atholl
William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London EC1M 6BQ, UK ; UAE General Hospital, Abu Dhabi, United Arab Emirates.
William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London EC1M 6BQ, UK.
Results Pharma Sci. 2011 Dec 7;2:1-8. doi: 10.1016/j.rinphs.2011.12.001. eCollection 2012.
Dissolution is the amount of substance that goes into solution per unit time under standardised conditions of liquid/solid interface, solvent composition and temperature. Dissolution is one of the most important tools to predict the in-vivo bioavailability and in some cases to determine bioequivalence and assure interchangeability.
To compare the differences in dissolution behaviour of solid dosage forms between innovators (reference products) and their generic counterparts (tested products).
Four replicates for each batch of 37 tested medicines was carried out using A PT-DT70 dissolution tester from Pharma Test. A total of 13 branded medicines and 24 generic counterparts were obtained locally and internationally to detect any differences in their dissolution behaviour. They were tested according to the British Pharmacopeia, European Pharmacopeia and the US Pharmacopeia with the rate of dissolution determined by ultra-violet Spectrophotometery.
Most tested medicines complied with the pharmacopoeial specifications and achieved 85% dissolution in 60 min. However, some generic medicines showed significant differences in dissolution rate at 60 and 120 min. Many generic medicines showed a slower dissolution rate than their branded counterparts such as the generic forms of omeprazole 20 mg. Some showed an incomplete dissolution such as the generic form of nifedipine 10 mg. Other generics showed faster dissolution rate than their branded counterpart such as the generic forms of meloxicam 15 mg. Moreover, some generics from different batches of the same manufacturer showed significant differences in their dissolution rate such as the generic forms of meloxicam 7.5 mg. Nevertheless, some generic medicines violated the EMA and the FDA guidelines for industry when they failed to achieve 85% dissolution at 60 min, such as the generic form of diclofenac sodium 50 mg.
Most medicines in this study complied with the pharmacopeial limits. However, some generics dissolved differently than their branded counterparts. This can clearly question the interchangeability between the branded and its generic counterpart or even among generics.
溶出度是指在液体/固体界面、溶剂组成和温度的标准化条件下,单位时间内进入溶液的物质的量。溶出度是预测体内生物利用度的最重要工具之一,在某些情况下可用于确定生物等效性并确保可互换性。
比较创新药(参比制剂)与其仿制药(受试制剂)固体剂型溶出行为的差异。
使用德国 Pharma Test 公司的 A PT-DT70 溶出度测试仪,对 37 种受试药品的每一批次进行 4 次重复测试。从本地和国际上共获取了 13 种品牌药和 24 种仿制药,以检测它们溶出行为的差异。根据英国药典、欧洲药典和美国药典进行测试,溶出速率通过紫外分光光度法测定。
大多数受试药品符合药典规定,在 60 分钟内达到 85%的溶出度。然而,一些仿制药在 60 分钟和 120 分钟时的溶出速率存在显著差异。许多仿制药的溶出速率比其品牌对应产品慢,如 20mg 奥美拉唑的仿制药。一些仿制药表现出不完全溶出,如 10mg 硝苯地平的仿制药。其他仿制药的溶出速率比其品牌对应产品快,如 15mg 美洛昔康的仿制药。此外,同一制造商不同批次的一些仿制药在溶出速率上也存在显著差异,如 7.5mg 美洛昔康的仿制药。然而,一些仿制药在 60 分钟时未达到 85%的溶出度,违反了欧洲药品管理局(EMA)和美国食品药品监督管理局(FDA)的行业指南,如 50mg 双氯芬酸钠的仿制药。
本研究中的大多数药品符合药典规定。然而,一些仿制药的溶出情况与其品牌对应产品不同。这显然对品牌药与其仿制药之间甚至仿制药之间的可互换性提出了质疑。